|
|
![]() |
![]() |
![]() |
![]() |
|
![]() |
|
![]() |
|
![]() |
|
![]() |
![]() |
![]() |
|
![]() |
|||||||||||||||||||||||||||||||||||||||||||||
| 1 | Conditions listed in this trial | ||||
| Cataract | |||||
| Uveitis | |||||
| 2 | More general conditions related to this trial | ||||
| Eye Diseases | |||||
| Lens Diseases | |||||
| Uveal Diseases | |||||
| 3 | Additional drug interventions recognized in this trial | ||||
| Heparin | |||||
| 4 | More general drug interventions related to this trial | ||||
| Anticoagulants | |||||
| Cardiovascular Agents | |||||
| Fibrin Modulating Agents | |||||
| Fibrinolytic Agents | |||||
| Hematologic Agents | |||||
| Molecular Mechanisms of Pharmacological Action | |||||
| Pharmacologic Actions | |||||
| Therapeutic Uses | |||||
| 5 | Sponsors listed in this trial | ||||
| National Eye Institute (NEI) | |||||